Ernexa Therapeutics Inc. Operating Lease Right-of-Use Assets
Ernexa Therapeutics Inc. (ERNA) had Operating Lease Right-of-Use Assets of $314.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-06
- 2026-06-30: Operating Lease, Right-of-Use Asset $314.00K.
- 2026-03-31: Operating Lease, Right-of-Use Asset $349.00K.
- 2025-12-31: Operating Lease, Right-of-Use Asset $453.00K.
- 2025-09-30: Operating Lease, Right-of-Use Asset $541.00K.
| Period end | Operating Lease, Right-of-Use Asset | Operating Lease, Right-of-Use Asset as first filed |
|---|---|---|
| 2026-06-30 | $314.00K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $349.00K 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $453.00K 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $541.00K 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $581.00K 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $619.00K 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $670.00K 10-K · filed 2026-03-13 | |
| 2024-09-30 | $719.00K 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $35.99M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $36.52M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $32.78M 10-K · filed 2025-03-12 | |
| 2023-09-30 | $34.86M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $35.36M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $989.00K 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $1.03M 10-K · filed 2024-03-14 | |
| 2022-12-29 | $800.00K 10-K · filed 2023-03-20 | |
| 2022-09-30 | $1.91M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $0.00 10-K · filed 2023-03-20 | $1.94M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $1.40M 10-K · filed 2024-03-14 | $1.09M 10-Q · filed 2022-07-01 |
| 2022-03-25 | $1.40M 10-K · filed 2023-03-20 | |
| 2021-12-31 | $2.57M 10-K · filed 2023-03-20 | |
| 2021-09-30 | $2.67M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $2.77M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $2.02M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $2.09M 10-K/A · filed 2022-07-01 | $36.00K 10-K · filed 2021-03-11 |
| 2020-09-30 | $5.00K 10-Q · filed 2020-11-13 | |
| 2020-06-30 | $44.00K 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $2.00M 10-Q · filed 2020-05-20 | |
| 2019-12-31 | $2.10M 10-K · filed 2021-03-11 | |
| 2019-09-30 | $2.18M 10-Q · filed 2019-11-01 | |
| 2019-06-30 | $2.25M 10-Q · filed 2019-08-12 | |
| 2019-03-31 | $2.26M 10-Q · filed 2019-05-14 | |
| 2019-01-02 | $2.34M 10-K · filed 2021-03-11 | |
| 2018-12-31 | $2.30M 10-K · filed 2019-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |